See-Hwee Yeo1, Wai-Ping Yau2. 1. Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Republic of Singapore. 2. Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Republic of Singapore. phaywp@nus.edu.sg.
Abstract
INTRODUCTION: Drug utilization and outcomes research in multi-ethnic Asian stroke populations is lacking. OBJECTIVES: Our objective was to examine temporal trends and predictors of drug utilization and outcomes in a multi-ethnic Asian stroke population. METHODS: This registry-based study included ischemic and hemorrhagic first-ever stroke patients hospitalized between 2009 and 2016. Utilization of medications included in-hospital thrombolytic agents, early antithrombotics (antiplatelets, anticoagulants) within 48 h of admission, and antithrombotics and statins at discharge. Outcomes analyzed were in-hospital all-cause mortality; 28-day, 90-day, and 1-year case fatality (CF); and discharge destination. RESULTS: Of the 36,615 included patients, 81.6% had ischemic stroke and 18.4% had hemorrhagic stroke (15.5% intracerebral hemorrhage [ICH] and 2.8% subarachnoid hemorrhage [SAH]). For ischemic stroke, the combined use of all three guideline medications (in-hospital thrombolytic therapy, as well as antithrombotics and statins at discharge) increased (P = 0.006). Being on the stroke pathway was associated with prescription of all three guideline medications in ischemic stroke. Decreasing trends for in-hospital mortality, 28-day, 90-day, and 1-year CF and proportion of patients discharged home without rehabilitation appointment were observed in ischemic stroke (P < 0.05) but not in ICH or SAH (apart from 28-day CF). Ischemic stroke patients who received guideline medications were less likely to die or be discharged to nursing homes and chronic sick hospitals. Hemorrhagic stroke patients prescribed statins at discharge were less likely to have 28-day and 1-year CF. CONCLUSIONS: Prescription of secondary stroke preventive medications (particularly in ischemic stroke) was associated with more favorable outcomes, highlighting the importance of physician adherence to evidence-based pharmacotherapy.
INTRODUCTION: Drug utilization and outcomes research in multi-ethnic Asian stroke populations is lacking. OBJECTIVES: Our objective was to examine temporal trends and predictors of drug utilization and outcomes in a multi-ethnic Asian stroke population. METHODS: This registry-based study included ischemic and hemorrhagic first-ever strokepatients hospitalized between 2009 and 2016. Utilization of medications included in-hospital thrombolytic agents, early antithrombotics (antiplatelets, anticoagulants) within 48 h of admission, and antithrombotics and statins at discharge. Outcomes analyzed were in-hospital all-cause mortality; 28-day, 90-day, and 1-year case fatality (CF); and discharge destination. RESULTS: Of the 36,615 included patients, 81.6% had ischemic stroke and 18.4% had hemorrhagic stroke (15.5% intracerebral hemorrhage [ICH] and 2.8% subarachnoid hemorrhage [SAH]). For ischemic stroke, the combined use of all three guideline medications (in-hospital thrombolytic therapy, as well as antithrombotics and statins at discharge) increased (P = 0.006). Being on the stroke pathway was associated with prescription of all three guideline medications in ischemic stroke. Decreasing trends for in-hospital mortality, 28-day, 90-day, and 1-year CF and proportion of patients discharged home without rehabilitation appointment were observed in ischemic stroke (P < 0.05) but not in ICH or SAH (apart from 28-day CF). Ischemic strokepatients who received guideline medications were less likely to die or be discharged to nursing homes and chronic sick hospitals. Hemorrhagic strokepatients prescribed statins at discharge were less likely to have 28-day and 1-year CF. CONCLUSIONS: Prescription of secondary stroke preventive medications (particularly in ischemic stroke) was associated with more favorable outcomes, highlighting the importance of physician adherence to evidence-based pharmacotherapy.
Authors: Gregg C Fonarow; Mathew J Reeves; Eric E Smith; Jeffrey L Saver; Xin Zhao; Dai Wai Olson; Adrian F Hernandez; Eric D Peterson; Lee H Schwamm Journal: Circ Cardiovasc Qual Outcomes Date: 2010-02-22
Authors: Valery L Feigin; Carlene M M Lawes; Derrick A Bennett; Suzanne L Barker-Collo; Varsha Parag Journal: Lancet Neurol Date: 2009-02-21 Impact factor: 44.182
Authors: Gustavo Saposnik; Michael D Hill; Martin O'Donnell; Jiming Fang; Vladimir Hachinski; Moira K Kapral Journal: Stroke Date: 2008-06-19 Impact factor: 7.914